4 completed, 2 terminated. 6 Phase 2, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 6 | Completed 4, Terminated 2 |
| Phase 1 | 1 | Completed 1 |
| Phase 3 | 1 | Terminated 1 |
Follow Familial Partial Lipodystrophy: new trials by email Literature Review of Familial Partial Lipodystrophy trials Research Report on Familial Partial Lipodystrophy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD) REGN4461, Matching Placebo - Familial Partial Lipodystrophy, Metabolic Abnormalities | Phase 2 | Terminated | Regeneron Pharmaceuticals | 20 | 2022-02-28 | 2025-10-16 |
| Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Partial Lipodystrophy (FPL) AKCEA-ANGPTL3-LRx - Familial Partial Lipodystrophy | Phase 2 | Completed | Akcea Therapeutics | 4 | 2018-06-15 | 2021-02-16 |
| Study of Gemcabene in Adults With FPLD 300mg Gemcabene, 600mg Gemcabene - Familial Partial Lipodystrophy, Hypertriglyceridemia | Phase 1 / Phase 2 | Completed | Elif Oral | 5 | 2018-03-13 | 2020-08-17 |
| Phase 2 Study of Obeticholic Acid for Lipodystrophy Patients Obeticholic Acid, Placebo - Familial Partial Lipodystrophy | Phase 2 | Completed | Abhimanyu Garg | 10 | 2016-06-01 | 2024-08-27 |
| The BROADEN Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Partial Lipodystrophy volanesorsen, Placebo - Familial Partial Lipodystrophy | Phase 2 / Phase 3 | Terminated | Akcea Therapeutics | 40 | 2015-12-28 | 2021-10-18 |
| CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy Metreleptin - Familial Partial Lipodystrophy, Nonalcoholic Steatohepatitis | Phase 2 | Completed | University of Michigan | 11 | 2015-09-29 | 2020-11-24 |
Lipodystrophy, Familial Partial (6) · Fatty Liver (2) · Non-alcoholic Fatty Liver Disease (2) · Diabetes Mellitus, Lipoatrophic (1) · Dyslipidemias (1) · Hypertriglyceridemia (1) · Lipid Metabolism Disorders (1) · Lipodystrophy (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6) · Genetic Diseases, Inborn (6) · Laminopathies (6) · Lipid Metabolism, Inborn Errors (6) · Metabolic Diseases (6) · Nutritional and Metabolic Diseases (6) · Skin Diseases (6) · Skin Diseases, Metabolic (6) · Skin and Connective Tissue Diseases (6) · Lipid Metabolism Disorders (5) · Lipodystrophy (5) · Digestive System Diseases (3) · Liver Diseases (3) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1)
ISIS 304801 (1) · Investigational New Drug Application (1) · gemcabene (1) · metreleptin (1) · obeticholic acid (1)
Akcea Therapeutics (2) · Abhimanyu Garg (1) · Elif Oral (1) · Regeneron Pharmaceuticals (1) · University of Michigan (1)
United States (6) · Belgium (1) · Brazil (1) · Canada (1) · France (1) · Germany (1) · Netherlands (1) · Russia (1) · Spain (1) · Turkey (Türkiye) (1)
Abhimanyu Garg, MD (1) · Elif A Oral, M.D. (1) · Elif A Oral, MD (1)
2015 (1)